Notably, ALT levels increased slightly during therapy to a final value of 53 U/L, most likely related to the patient’s pronounced metabolic comorbidity and obesity (BMI at BLV discontinuation, 39.5 kg/m2). The gene discussed is GPT; the disease is obesity disorder.